Introduction
Lenalidomide (LEN) is commonly used in the treatment of multiple myeloma (MM) as induction or maintenance therapy following autologous hematopoietic stem cell transplant (Auto-HSCT). It belongs to the class of immunomodulatory drugs (IMiDs) which acts by downregulating transcription factors like Ikaros (IKZF1) and Aiolos (IKZF3). These transcription factors increase production of interferon regulatory factor (IRF4) which, in turn, regulates malignancyspecific gene expression in MM [1] . It functions as an antimyeloma agent by stimulating the proliferation of anti-CD3 (cluster of differentiation 3) stimulated T cells and inhibiting the secretion of proinflammatory cytokines and angiogenic factors in the cells [2] [3] . LEN is chemically related to its parent drug, thalidomide, but with a better side effect profile. Adverse effects of LEN may include fatigue, muscle cramps, thrombocytopenia, neutropenia, dizziness ,   1  2  3  2   3  2  4  3  2 tremors, and neuropathy. Herein, we present a case of possible association between LEN use and tardive dyskinesia (TD). She received three cycles of carfilzomib, lenalidomide, and dexamethasone (KRd) for remission induction from January 30 to March 2017 followed by high-dose melphalan and auto-HSCT as consolidation on July 6, 2017. She was started on maintenance LEN (10 mg/day) in October of 2017. Approximately three months after starting LEN maintenance on January 24, 2018, she complained of acute onset jaw pain that evolved into abnormal movements, such as continuous lip-smacking, blinking of eyes, frowning, and chewing movements, which further progressed to uncontrolled verbal tics and difficulty with speech over the next few days. One week after the onset of her symptoms, the LEN maintenance therapy was stopped. Gradually, her symptoms worsened and were managed with lorazepam. She underwent a neurological evaluation, including computerized tomography (CT) scan and magnetic resonance imaging (MRI) of the brain, which was negative. The abnormal involuntary movement scale (AIMS) was used to detect TD and also to follow the severity of TD symptoms over time. The rating of two or higher is diagnostic for TD. Table 1 shows the patient's score on her first neurologist visit.
Case Presentation

Score Facial and Oral Movements
Muscles of facial expression, e.g., movements of forehead, eyebrows, periorbital area, cheeks. Include frowning, blinking, grimacing of the upper face.
2.5
Lips and perioral area, e.g., puckering, pouting, smacking. 3
Jaw, e.g., biting, clenching, chewing, mouth opening, lateral movement. 2
Tongue. Rate only increase in movement both in and out of the mouth, not an inability to sustain movement. 4
Extremity Movements
Upper (arms, wrists, hands, fingers). Include movements that are choreic (rapid, objectively purposeless, irregular, spontaneous) or athetoid (slow, irregular, complex, serpentine). Do not include tremor (repetitive, regular, rhythmic movements).
3
Lower (legs, knees, ankles, toes), e.g., lateral knee movement, foot tapping, heel dropping, foot squirming, and inversion and eversion of the foot. 1
Trunk Movements
Neck, shoulders, hips, e.g., rocking, twisting, squirming, and pelvic gyrations. Include diaphragmatic movements 2
Global Judgments
Severity of abnormal movements overall 3
Incapacitation due to abnormal movements. 
TABLE 1: Abnormal involuntary movement scale (AIMS)
Her symptoms were managed with diphenhydramine, diazepam, and later with clonazepam. Her home medications included acyclovir, aspirin, dexamethasone, ibuprofen, loratadine, magnesium oxide, and lorazepam. None of these are associated with drug-induced tardive-like dyskinesia/dystonia. The patient continued clonazepam, leading to a gradual improvement in her symptoms. Since January 24, 2018, she has not taken LEN, and her disease is in a remission phase.
Discussion
Lenalidomide therapy has significantly improved the response rates and progression-free survival among patients with MM [4] . Lenalidomide is derived from thalidomide but is more potent than its parent drug. The former has an additional amino group at position 4 of the phthaloyl ring and removal of a carbonyl group from the phthaloyl ring (as shown in Figure 1 ) [5] [6] . Theoretically, this similarity in structure may lead to an overlap in toxicities, i.e. neuropathies (occurring in more than 50% of patients on thalidomide) [7] [8] . However, the exact pathophysiology leading to central nervous system (CNS) side-effects caused by IMiDs is poorly understood, and there is no proposed mechanism for interaction of lenalidomide with CNS leading to TD. Neurologic side effects that may occur with the use of LEN include headache (1.1%), dizziness (3.4%), tremors (1.1%), peripheral neuropathy (1.7%), and insomnia (1.1%), and very rarely, TD (which is commonly seen with the use of antipsychotics) [9] [10] . LENassociated TD was especially found to be more common in females, 60+ years old, patients taking the drug for < 1 month who also take the medication metoclopramide, and have indigestion. Extrapyramidal symptoms (EPS) have also been reported with the use of thalidomide. In a study by Marchetti et al., 38 patients (60.3%) on thalidomide experienced neurologic side effects and 1.6% patients had extrapyramidal symptoms [11] . Similarly, Crystal et al. reported an acute worsening of Parkinson's disease with the use of thalidomide, which had been given to a patient of myelofibrosis with myeloid metaplasia. His symptoms partly resolved within two weeks of discontinuation of thalidomide [12] .
FIGURE 1: Chemical structure of immunomodulatory drugs
Common structural features are shown in black, whereas red indicates the differences between the two structures.
O: oxygen; NH: imide group; N: nitrogen, NH2: amino group
Modified figure from Ríos-Tamayo et al. [6] Our patient had no history of past exposure to medications associated with drug-induced TD/dystonia at the time of her symptoms. Neurologic adverse effects, including extrapyramidal side effects, can occur with thalidomide; the structural similarity between these drugs can potentially contribute to similar toxicities and could possibly be the reason for TD caused by LEN in this patient. Further studies are suggested to establish the association of TD with LEN use in MM patients.
Conclusions
LEN is a medication commonly used during induction and maintenance therapy of MM that significantly improves the progression-free survival and overall survival in these patients. Neurologic side effects commonly associated with LEN therapy are peripheral neuropathy, dizziness, dysgeusia, headache, tremor, somnolence, and memory impairment; however, it may cause TD rarely. TD can be socially and physically disabling for the patient, causing impairment of mobility, speech, and interference with eating. This makes it imperative to report these rare and unusual side effects for prompt management. Patient education is also important for early detection and treatment. Further studies should be carried out to establish the association of LEN with the development of TD focusing on how the structural similarity between the LEN and thalidomide can potentially contribute to such toxicities.
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